Biomea Fusion, Inc.

NasdaqGS BMEA

Biomea Fusion, Inc. Price to Sales Ratio (P/S) on February 05, 2025: 24.54

Biomea Fusion, Inc. Price to Sales Ratio (P/S) is 24.54 on February 05, 2025, a -77.28% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Biomea Fusion, Inc. 52-week high Price to Sales Ratio (P/S) is 109.48 on February 27, 2024, which is 346.03% above the current Price to Sales Ratio (P/S).
Biomea Fusion, Inc. 52-week low Price to Sales Ratio (P/S) is 22.01 on January 03, 2025, which is -10.34% below the current Price to Sales Ratio (P/S).
Biomea Fusion, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 53.14.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGS: BMEA

Biomea Fusion, Inc.

CEO	Mr. Thomas Andrew Butler
IPO Date	April 16, 2021
Location	United States
Headquarters	900 Middlefield Road
Employees	107
Sector	Healthcare
Industries Biotechnology Chemicals & Advanced Materials Clinical Trials Pharmaceuticals

Description

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Key trends

Past 5 years